CASI Pharmaceuticals (CASI) AI Stock Analysis

• Market Cap: $32.50M
• Dividend Yield: N/A
• Average Volume (3M): 10.19K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.35
• Revenue Growth: -13.78%
• EPS Growth: -34.45%
• Country: US
• Employees: 176
• Sector: Healthcare
• Sector Strength: 71
• Industry: Biotechnology
• EPS (TTM): -2.70
• Shares Outstanding: 15,492,681
• 10 Day Avg. Volume: 13,563
• 30 Day Avg. Volume: 10,193
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 1.01
• Price to Cash Flow (P/CF): N/A
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $4.00
• Price Target Upside: 90.48% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

CASI Pharmaceuticals has a low overall stock score, primarily due to poor financial performance characterized by declining revenues, high leverage, and negative cash flow. Technical indicators suggest a bearish trend, and the valuation is hampered by a negative P/E ratio and lack of dividends. The company needs to improve its financial stability and operational efficiency to enhance its stock performance.

CASI Pharmaceuticals Business Overview & Revenue Model

Company Description

CASI Pharmaceuticals (CASI) is a biopharmaceutical company focused on the acquisition, development, and commercialization of innovative therapeutics addressing cancer and other unmet medical needs. The company operates within the pharmaceutical and biotechnology sectors, offering a diverse portfolio of products that include both proprietary and in-licensed drugs. CASI's core product line includes oncology treatments and specialty therapeutics aimed at enhancing patient outcomes in China and other select markets.

How the Company Makes Money

CASI Pharmaceuticals generates revenue through the commercialization of its pharmaceutical products, primarily focusing on oncology and specialty therapeutics. The company's revenue streams include the direct sale of its developed drugs and in-licensed products to healthcare providers and distributors. Additionally, CASI may engage in strategic partnerships and collaborations with other pharmaceutical firms to co-develop or co-market products, providing additional income through milestone payments, royalties, and licensing fees. Factors such as regulatory approvals, market penetration, and product performance in clinical settings significantly influence CASI's earnings.

CASI Pharmaceuticals Financial Statement Overview

Summary

CASI Pharmaceuticals faces significant financial challenges, with declining revenues, negative profitability margins, and increasing leverage. The balance sheet shows financial instability, characterized by high liabilities and zero operational cash generation, posing substantial risks for financial sustainability.

Income Statement

CASI Pharmaceuticals shows a declining revenue trend with a significant drop from $43.11M in 2022 to $21.27M TTM. The company is experiencing negative net profit margins, with TTM net income at -$30.35M. Gross profit margin has decreased over the years, and EBIT and EBITDA margins remain negative. These factors suggest challenges in achieving profitability.

Balance Sheet

The company's debt-to-equity ratio has increased due to rising liabilities and decreasing equity, indicating higher leverage. The equity ratio has declined, highlighting reduced financial stability. Return on equity is negative due to persistent losses. The balance sheet reflects financial instability, with high liabilities relative to equity.

Cash Flow

CASI's cash flow statement shows zero operating and free cash flow in TTM, indicating challenges in generating cash from operations. Historical data reveals negative free cash flow, with no evident growth trajectory. The operating cash flow to net income ratio is unfavorable, suggesting liquidity issues.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
21.27M	33.88M	43.11M	30.17M	15.14M	4.13M
	Gross Profit
11.74M	20.05M	27.28M	17.61M	5.63M	196.00K
	EBIT
-36.67M	-25.08M	-26.49M	-35.28M	-33.31M	-39.99M
	EBITDA
-31.07M	-21.54M	-24.07M	-32.75M	-31.35M	-37.43M
	Net Income Common Stockholders
-30.35M	-26.94M	-39.41M	-37.77M	-62.57M	-51.41M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
9.69M	30.77M	51.34M	48.57M	66.37M	54.25M
	Total Assets
10.02M	75.27M	96.23M	138.30M	127.73M	102.63M
	Total Debt
7.24M	21.24M	1.34M	2.17M	1.29M	2.20M
	Net Debt
-2.41M	4.16M	-45.77M	-36.54M	-55.77M	-51.42M
	Total Liabilities
9.20M	51.10M	29.30M	30.34M	24.16M	8.97M
	Stockholders Equity
817.26K	24.16M	44.57M	84.50M	81.54M	73.00M
Cash Flow		Free Cash Flow
0.00	-22.21M	-26.70M	-42.34M	-45.21M	-37.26M
	Operating Cash Flow
0.00	-19.97M	-21.09M	-26.84M	-25.89M	-23.24M
	Investing Cash Flow
0.00	-9.67M	31.16M	-20.69M	-20.72M	-28.06M
	Financing Cash Flow
0.00	-907.00K	-3.27M	29.64M	47.15M	22.05M

CASI Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CASI, the sentiment is Neutral. The current price of 2.1 is below the 20-day moving average (MA) of 2.14, below the 50-day MA of 2.28, and below the 200-day MA of 4.48, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 47.21 is Neutral, neither overbought nor oversold. The STOCH value of 19.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CASI.

CASI Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	50 Neutral	$5.52B	2.98	-43.78%	2.78%	16.94%	3.55%
CASI	41 Neutral	$32.50M	―	-301.80%	―	-13.78%	-34.45%
MDAI	41 Neutral	$31.65M	―	256.43%	―	238.96%	35.96%
FEMY	39 Underperform	$30.95M	―	-182.18%	―	51.97%	9.94%
CLGN	38 Underperform	$28.06M	―	-79.46%	―	-95.30%	-135.89%
PYPD	30 Underperform	$25.99M	―	-1038.73%	―	―	-85.67%
GBIO	30 Underperform	$25.06M	―	-91.02%	―	236.92%	-0.57%